UNITED HEALTH PRODUCTS, INC. (OTCMKTS:UEEC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0
UNITED HEALTH PRODUCTS, INC. (OTCMKTS:UEEC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED HEALTH PRODUCTS, INC. (OTCMKTS:UEEC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, Compensatory arrangements of Certain Officers

On November 24, 2020, the Board of Directors approved a succession proposal by Douglas Beplate, Chief Executive Officer, whereupon he would step down from his current management position and the Company would appoint Brian Thom as Mr. Beplate’s successor to the position of Chief Executive Officer, effective December 1, 2020. Mr. Beplate shall continue to serve as a member of the Board of Directors and as its Chairman. Mr. Thom would also be appointed effective January 1, 2021 to serve as a member of the Board of Directors to fill a currently existing vacancy on the Board.

On November 24, 2020, Nate Knight submitted his resignation, which the Company accepted, from his position as Chief Financial Officer and a director of the Company. The Company and Mr. Knight also agreed to terminate his services agreement effective upon his resignation. Louis Schiliro, who currently services as Chief Operating Officer was appointed to the Board of Directors to fill the vacancy resulting from Mr. Knight’s resignation. Additionally, Kristofer Heaton was appointed by the Board of Directors to serve as Vice President of Finance and as the Company’s Principal Financial Officer.

On December 1, 2020, the Company entered an “at will” services agreement with Mr. Thom for his CEO role. This agreement is appended hereto as Exhibit 10.1. Mr. Thom shall receive a monthly fee of $15,000. He is also entitled to a Restricted Stock Unit Award of 11,500,000 shares, which shall vest based upon performance as outlined in the RSU Agreement, which is appended hereto as Exhibit 10.2. Brian Thom has served as a consultant to the Company since April 2020 overseeing finance and business development activities. He brings over 20 years of corporate finance experience and a successful track record of helping fast growing companies across a broad range of industries to raise capital and create shareholder value. Over the course of his career he spent a decade with JPMorgan’s global Mergers and Acquisitions group and five years leading the Americas Corporate Finance group with Société Générale, a multi-national European investment bank, among other entrepreneurial pursuits. During this time, Mr. Thom played a major role in over 60 M&A and equity placement transactions with an aggregate transaction value in excess of $200 billion.

The Company is currently negotiating an “at will” services agreement with Mr. Heaton for his VP Finance and CFO role, under which proposes a monthly fee of $7,500 and Restricted Stock Unit Award totaling 1,000,000 shares (inclusive of 500,000 RSUs previously granted) which shall vest based upon performance metrics.

Kristofer Heaton is a CPA and began his career with a large bank in Salt Lake City in 2004. In 2006, he moved to public accounting and gained experience in various industries while working for eight years for various firms. Mr. Heaton founded his own firm “Heaton & Company, PLLC” in 2015 which specializes in audits of public companies and which has provided non-audit accounting and administrative services to the Company since 2017. Mr. Heaton will continue his accounting practice in addition to position with the Company. Mr. Heaton obtained his bachelor’s degree in Accounting from Brigham Young University and his master’s degree in Accounting from Weber State University.

Reference is made to the Company’s Form 10-K for the fiscal year ended December 31, 2019 for a description of the biography of Louis Schiliro.

Item 8.01. Other Events

On November 24, 2020, the Company issued a press release, a copy of which is appended hereto as Exhibit 99.1.

Item 9.01.  Financial Statements and Exhibits.

 

United Health Products, Inc. Exhibit

To view the full exhibit click here

About UNITED HEALTH PRODUCTS, INC. (OTCMKTS:UEEC)

United Health Products, Inc. is a product development and solutions company. The Company develops, manufactures and markets hemostatic gauze for the healthcare and wound care sectors. The Company’s product, HemoStyp, is derived from regenerated oxidized cellulose and designed to absorb exudate/drainage from wounds and to help control bleeding. The Company is focused on identifying new markets and applications for its product. The Company has received orders from the dental and medical markets and is pursuing various markets for HemoStyp, including the medical, sports and veterinary sectors. Its HemoStyp Hemostatic Gauze is a hemostatic agent that controls bleeding from open wounds and body cavities. Its hemostatic gauze product line includes various configurations. Its hemostatic gauze product line includes dental gauze for oral surgery, approximately four versions of Trauma Gauze for battlefield trauma and approximately two island dressings to support intravenous procedures.